Quick news: top level event of pharmaceutical innovation investment won support of authoritative organizations again

-- national major new drug special office and science and technology development center become the supporting Party of the conference source: China Council for the promotion of drugs 2016-10-26 today, China Council for the promotion of pharmaceutical innovation received "major new drug creation" from the state The confirmation of the implementation and Management Office of major science and technology projects (hereinafter referred to as the major new drug project office) and the research center of medical and health science and technology development of the national health and Family Planning Commission (hereinafter referred to as the science and Technology Development Center) has officially become the supporting unit of the first China Pharmaceutical Innovation and Investment Conference (hereinafter referred to as the conference) So far, there have been eight supporting units for the conference, and the remaining six are the Bureau of science and technology promotion and development of the Chinese Academy of Sciences, the Chinese Academy of Medical Sciences, the Chinese Academy of traditional Chinese medicine, the Chinese Academy of Military Medical Sciences of the people's Liberation Army, the "thousand talents plan" expert Association of the central organization department and Suzhou Industrial Park The national major science and technology project of "major new drug creation" is one of the major national science and technology projects organized and implemented in accordance with the national medium and long term plan for science and technology development (2006-2020) The new drug major project office is the leading organization and Planning Management Department of the national new drug major project, and the science and technology development center is the working organization responsible for the specific project management of the new drug major project, including review and approval, process management, final acceptance and corresponding fund management Since 2008, major national new drug projects have made important achievements, significantly improving the level of drug innovation and clinical drug access in China, and played an important role in promoting the development of pharmaceutical innovation in China The first China Pharmaceutical Innovation and investment conference co sponsored by China pharmaceutical innovation promotion association and China Securities Association is now in orderly progress The conference is closely linked with "promoting the combination of social capital and innovation, improving the innovation ability of the pharmaceutical industry" Focusing on important topics such as pharmaceutical innovation and investment policies, innovative drug R & D trends, etc., it has set up high-level dialogues between scientists and the investment community, global launch of innovative drug clinical data, new project roadshows of pharmaceutical enterprises and related policy forums, etc., which have received continuous attention and warm response from the industry and the investment community Up to now, more than 450 pharmaceutical enterprises, scientific research institutes and investment institutions have signed up for the conference and roadshow, including more than 150 investment institutions Among the nearly 80 enterprises that have participated in the clinical data launch and project roadshow, many enterprises and institutions are undertaking the research of major national new drug special topics, which is actually the top grand meeting of Chinese pharmaceutical innovation and investment industry In addition, China pharmaceutical innovation promotion association and China Securities Association have reached a consensus that they will rely on the inter agency private product quotation and service system to open the pharmaceutical innovation industry sector, provide innovative pharmaceutical enterprises with information display, diversified private equity financing, private equity financing and other services, and attract more social capital to participate in pharmaceutical innovation The major new drug special office and the science and technology development center officially became the supporter of the conference, reflecting the high attention and expectation of the two departments to promote the cooperation between the pharmaceutical innovation and the investment community, and injecting new energy into the success of the conference With the strong support of the government and other relevant sectors, this conference will become an important milestone for the Chinese pharmaceutical innovation community to work closely with the investment community to promote the accelerated development of pharmaceutical innovation.